JP2023551193A5 - - Google Patents
Info
- Publication number
- JP2023551193A5 JP2023551193A5 JP2023530546A JP2023530546A JP2023551193A5 JP 2023551193 A5 JP2023551193 A5 JP 2023551193A5 JP 2023530546 A JP2023530546 A JP 2023530546A JP 2023530546 A JP2023530546 A JP 2023530546A JP 2023551193 A5 JP2023551193 A5 JP 2023551193A5
- Authority
- JP
- Japan
- Prior art keywords
- inh
- administered
- formulation according
- dose
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063116405P | 2020-11-20 | 2020-11-20 | |
| US63/116,405 | 2020-11-20 | ||
| PCT/US2021/059872 WO2022109124A1 (en) | 2020-11-20 | 2021-11-18 | Method for treating antibody-mediated rejection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023551193A JP2023551193A (ja) | 2023-12-07 |
| JP2023551193A5 true JP2023551193A5 (https=) | 2024-11-25 |
Family
ID=78918649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023530546A Pending JP2023551193A (ja) | 2020-11-20 | 2021-11-18 | 抗体関連型拒絶反応を処置するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240000908A1 (https=) |
| EP (1) | EP4247416A1 (https=) |
| JP (1) | JP2023551193A (https=) |
| KR (1) | KR20230110563A (https=) |
| CN (1) | CN116568327A (https=) |
| AU (1) | AU2021381360A1 (https=) |
| CA (1) | CA3198740A1 (https=) |
| WO (1) | WO2022109124A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025067383A1 (zh) * | 2023-09-28 | 2025-04-03 | 荣昌生物制药(烟台)股份有限公司 | 用TACI-Fc融合蛋白治疗抗体介导性排斥反应的方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3228502A1 (de) | 1982-07-30 | 1984-02-02 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung des c1-inaktivators und seine verwendung |
| DE4222534A1 (de) | 1992-07-09 | 1994-01-13 | Behringwerke Ag | Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura |
| DE4244735A1 (de) | 1992-08-24 | 1994-03-31 | Behringwerke Ag | Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen |
| DE69534265T2 (de) | 1994-12-12 | 2006-05-04 | Beth Israel Deaconess Medical Center, Inc., Boston | Chimäre zytokine und ihre verwendung |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US7053176B1 (en) | 1999-09-16 | 2006-05-30 | Altana Pharma Ag | Combination of C1-INH and lung surfactant for the treatment of respiratory disorders |
| AU2003210806A1 (en) | 2002-03-05 | 2003-09-22 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| PL2298347T3 (pl) | 2003-05-06 | 2016-03-31 | Bioverativ Therapeutics Inc | Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| DK1641823T3 (da) | 2003-06-12 | 2011-12-12 | Lilly Co Eli | GLP-1-analog fusionsproteiner |
| RU2370276C2 (ru) | 2003-12-31 | 2009-10-20 | Мерк Патент Гмбх | Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ |
| PL2380587T3 (pl) | 2005-12-21 | 2018-03-30 | Pharming Intellectual Property B.V. | Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu |
| CA2678001C (en) | 2007-02-12 | 2017-07-11 | Stefan Schulte | Therapeutic application of kazal-type serine protease inhibitors |
| EP4162947A1 (en) | 2013-11-22 | 2023-04-12 | Takeda Pharmaceutical Company Limited | Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor |
| US20160130324A1 (en) | 2014-10-31 | 2016-05-12 | Shire Human Genetic Therapies, Inc. | C1 Inhibitor Fusion Proteins and Uses Thereof |
| US20190175683A1 (en) * | 2016-08-05 | 2019-06-13 | Csl Behring Gmbh | Pharmaceutical formulations of c1 esterase inhibitor |
-
2021
- 2021-11-18 WO PCT/US2021/059872 patent/WO2022109124A1/en not_active Ceased
- 2021-11-18 JP JP2023530546A patent/JP2023551193A/ja active Pending
- 2021-11-18 AU AU2021381360A patent/AU2021381360A1/en active Pending
- 2021-11-18 CA CA3198740A patent/CA3198740A1/en active Pending
- 2021-11-18 US US18/253,485 patent/US20240000908A1/en active Pending
- 2021-11-18 EP EP21827458.7A patent/EP4247416A1/en active Pending
- 2021-11-18 CN CN202180077987.5A patent/CN116568327A/zh active Pending
- 2021-11-18 KR KR1020237020679A patent/KR20230110563A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009519257A5 (https=) | ||
| JP2008538564A5 (https=) | ||
| JP2016514132A5 (https=) | ||
| JP2016065094A5 (https=) | ||
| JP2017503820A5 (https=) | ||
| JP2013533858A5 (https=) | ||
| JP2018522851A5 (https=) | ||
| JP2021502980A5 (https=) | ||
| JP2018506550A5 (https=) | ||
| JP2016537380A5 (https=) | ||
| JP2018514510A5 (https=) | ||
| JP2012102122A5 (https=) | ||
| JP2006513184A5 (https=) | ||
| JP2020533302A5 (https=) | ||
| JP2018530578A5 (https=) | ||
| IT8922725A1 (it) | Impiego di immunomodulanti come agenti sinergici di chemioterapici nella terapia dei tumori | |
| JP2018512402A5 (https=) | ||
| JP2017537927A5 (https=) | ||
| JP2023551193A5 (https=) | ||
| FI3630177T3 (fi) | Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle | |
| JP2022501332A5 (https=) | ||
| JP2019534251A5 (https=) | ||
| JP2021501800A5 (https=) | ||
| Highsmith et al. | Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma | |
| JP2009538916A5 (https=) |